The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 357:1771-1774 October 25, 2007 Number 17
NextNext

Germ-Cell Tumors

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Einhorn, L. H.
-PubMed Citation
To the Editor: Einhorn et al. (July 26 issue)1 report on high-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. One of the limitations of this study is the lack of a validation set for the prognostic scoring system. We addressed this lack of validation with support from the Orchid Cancer Appeal, by using our prospective database of 112 patients from a single institution who received dose-dense rather than high-dose chemotherapy for the treatment of germ-cell tumors.2,3 The characteristics of the patients in our cohort and those of the patients in the study by Einhorn et al. were very similar, . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.